highly significantp <0.001
The mean reduction at 6 months follow up in the patients compared to baseline in the parameters like AST (50.31%), ALT (48.77%) and TG (59.71%) was highly significant ( p <0.001).
The mean reduction at 6 months follow up in the patients compared to baseline in the parameters like AST (50.31%), ALT (48.77%) and TG (59.71%) was highly significant ( p <0.001).
Eradication rates were higher in concomitant therapy 32/33 (96.97%) than sequential therapy 17/21 (80.96%) but did not reach statistical significance ( p =0.06).